Martin Dietrich, MD, PhD

Dr Dietrich discusses the rationale for testing for HER2 and MET mutations in patients with NSCLC, as well as best practices for implementing this testing.

Martin F. Dietrich, MD, PhD, discusses the efficacy and safety profiles of taletrectinib for the management of ROS1-positive non–small cell lung cancer.

Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, discuss how KRAS(ON) inhibitors differ in mechanism from KRAS(OFF) inhibitors.

Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, discuss the evolving role of KRAS G12C and pan-KRAS inhibitors in pancreatic cancer.

Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, discuss the prevalence of RAS mutations in pancreatic ductal adenocarcinoma.

Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, detail the continued interest in RAS inhibition for pancreatic ductal adenocarcinoma.

Panelists discuss how implementing the new standard of combination therapies requires thorough patient education, prophylactic management of toxicities, and multidisciplinary support to optimize outcomes for patients with EGFR-mutant lung cancer.

Panelists discuss how optimizing treatment duration, using local therapy for oligometastatic disease, and understanding the limitations of current biomarkers are important considerations in developing effective sequencing strategies for EGFR-mutant lung cancer.

Panelists discuss how central nervous system (CNS) progression presents unique challenges in treatment decision-making, highlighting the importance of brain imaging surveillance and considering approaches that maintain CNS disease control while addressing systemic progression.

Panelists discuss how many patients never receive second-line therapy, emphasizing the critical importance of selecting the optimal first-line treatment and monitoring patients closely to identify progression early.

Panelists discuss how subsequent therapy after initial disease progression should consider patient symptomatology, biomarker testing through tissue or liquid biopsies, and potential treatment options including MET-targeted approaches or chemotherapy combinations.

Panelists discuss how quality of life considerations, including prophylactic medications to prevent dermatologic toxicities and infusion-related reactions, are crucial when implementing EGFR-targeted therapies, especially the MARIPOSA regimen.

Panelists discuss how the overall survival benefit from the MARIPOSA regimen (amivantamab plus lazertinib) with a hazard ratio of 0.75 and projected survival improvement exceeding 1 year represents a significant advancement that must be weighed against toxicity concerns.

Panelists discuss how conversations with patients about treatment options have become more complex and nuanced, requiring thorough explanation of efficacy data and adverse effects while adapting to each patient’s level of understanding and involvement.

Panelists discuss how the treatment landscape for EGFR-mutant non–small cell lung cancer has evolved with new combination therapies like osimertinib plus chemotherapy (FLAURA2) and amivantamab plus lazertinib (MARIPOSA) challenging osimertinib monotherapy as the standard of care.

Panelists discuss what they would like to see in future trials to address the unmet needs and challenges in treating patients diagnosed with lung large cell neuroendocrine carcinoma (LCNEC).

Panelists discuss any upcoming trials on the horizon that they are excited about in the context of lung large cell neuroendocrine carcinoma (LCNEC) treatment.

Panelists discuss ongoing lung large cell neuroendocrine carcinoma (LCNEC) trials involving both familiar and novel agents, including phase 2 durvalumab + EP (1L), phase 2 LCNEC-ALPINE atezolizumab + EP (1L), phase 1/2 SKYBRIDGE PT217 DLL3/CD47 bispecific antibody (2L+), and phase 1 LB2102 DLL2-directed CAR T (2L+).

Panelists discuss ongoing trials with BI 764532 and their potential impact on the treatment of lung large cell neuroendocrine carcinoma (LCNEC).

Panelists discuss how novel targeted therapies, such as T-cell engagers, could improve outcomes for patients with lung large cell neuroendocrine carcinoma (LCNEC) and other neuroendocrine cancers (NECs).

Panelists discuss their impressions of the LANCE pilot study for atezolizumab in lung large cell neuroendocrine carcinoma (LCNEC) and its potential impact on treatment strategies.

Panelists discuss the typical treatment approach for patients with lung large cell neuroendocrine carcinoma (LCNEC), the patient-specific factors considered in first-line treatment selection, insights from the ASCO 2024 retrospective studies on first-line systemic treatment outcomes, and key considerations for choosing a second-line treatment strategy.

Panelists discuss the typical treatment approach for patients with lung large cell neuroendocrine carcinoma (LCNEC), the patient-specific factors considered in first-line treatment selection, insights from the ASCO 2024 retrospective studies on first-line systemic treatment outcomes, and key considerations for choosing a second-line treatment strategy.

Panelists discuss the vital multidisciplinary coordination needed to optimize care for patients with lung large cell neuroendocrine carcinoma (LCNEC), including the roles of various specialists, ensuring alignment on diagnosis, risk assessment, and treatment goals, and the importance of involving the patient in these discussions.

Panelists discuss the challenges encountered with molecular or pathology testing for lung large cell neuroendocrine carcinoma (LCNEC) and how treatment plans are determined when testing is not feasible.

Panelists discuss the factors that influence the decision to perform a fine needle aspirate vs an incisional biopsy, whether testing is conducted in-house or at a central laboratory, and how the results of these tests impact the treatment plan for patients with lung large cell neuroendocrine carcinoma (LCNEC).

Panelists discuss how biomarker testing for lung large cell neuroendocrine carcinoma (LCNEC) is approached, covering the frequency and types of tests used, such as NGS, the timing of DLL3 testing, and the factors influencing the choice between fine needle aspirate and other biopsy techniques.

Panelists discuss how lung large cell neuroendocrine carcinoma (LCNEC) is diagnosed, including the challenges associated with its differential diagnosis.

Panelists discuss how the characterization and classification of lung large cell neuroendocrine carcinoma (LCNEC) has evolved over the past decade, highlighting the clinical heterogeneity of these tumors and how it is navigated in clinical practice.

Panelists discuss how lung large cell neuroendocrine carcinoma (LCNEC) is characterized by its biology, incidence, risk factors, clinical presentation, and prognosis, while addressing the challenges, unmet needs, and the trial data required to guide testing and treatment guidelines for this rare cancer.